Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/27985| Title: | Critical shortage in BCG immunotherapy: How did we get here and where will it take us? | Austin Authors: | Harvey, Michael;Chislett, Bodie ;Perera, Marlon ;Lawrentschuk, Nathan;Bolton, Damien M ;Jack, Gregory S | Affiliation: | Uro-Oncology Service, Peter MacCallum Cancer Centre, Victoria Comprehensive Cancer Centre, Melbourne, Australia Department of Urology, Western Health, Melbourne, Australia Urology Olivia Newton-John Cancer Wellness and Research Centre |
Issue Date: | 2022 | Date: | 2021-11-05 | Publication information: | Urologic Oncology 2022; 40(1): 1-3 | Abstract: | Intravesical Bacillus Calmette-Guérin vaccine, one of the most successful bio-therapies to date, has been the gold standard treatment for non-muscle invasive bladder cancer for 44 years. International shortages have necessitated rationing this life-saving medication with deleterious effects on the primary treatment of high-grade non-muscle invasive bladder cancer. Understanding the history of intravesical Bacillus Calmette-Guérin gives us insight into the current shortages and future perspectives for novel immunotherapy opportunities against this deadly disease. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/27985 | DOI: | 10.1016/j.urolonc.2021.09.022 | Journal: | Urologic Oncology | PubMed URL: | 34750053 | Type: | Journal Article | Subjects: | Bacillus Calmette-Guérin vaccine Bladder cancer Immunotherapy Tuberculosis |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.